Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (January 2015)
38 slides from Sorrento Therapeutics's investor presentation, Jan 12, 2015

Slide 1: Next-Generation Cancer Therapeutics
Exhibit 99.2 Exhibit 99.2 Next-Generation January 2015 Cancer Therapeutics

Slide 2: Safe Harbor
Safe Harbor This regarding “believe,” Actual Company candidates, available other 2filings presentation factors with results to our may “estimate” including the Statement affecting business, may not Securities Company contains proceed differ and timelines, such NASDAQ: technologies from “continue” as

Slide 3: A Comprehensive Cancer Company
A Comprehensive Deep Novel Small Molecules Cytotoxics CYNVILOQ™ Bispecific Cancer Targeted MYC 3CYNVILOQ, and inhibitor Biologics breakthrough Pain Therapy Complementary Abs Therapy Immunotherapy CAR.TNK, Intractable Anti-VEGR2 PD-1, Cell Targeted Oncology Care combination Supportive PD-L1, CAR.TNK

Slide 4: Corporate Pipeline Events
Corporate Pipeline cellular Tumor-attacking “The Immunotherapy Company” Antibody Pilot CYNVILOQ Licensing Pharmaceutical Exclusive 4conjugates PK First immunotherapy Unlocking data global agreement research Events joint (ADCs) autoimmune albumin-bound from for venture Soon-Shiong, NeuKoplast) partne

Slide 5: Pipeline by indication and phase
Deep Intractable Significant INDICATION Metastatic CYNVILOQ™ RTX G-MAB Bi-Specific PD-L1.TNK, ADC MYC *Abraxane® 5PDL1.TNK, VEGFR2, and Inhibitor Immuno-oncology Complementary Breast Opportunities Ab CD123.TNK, (paclitaxel CD123.TNK, >PD-L1/c-MET; Solid Non-Small c-MET, Cancer TARGET Cancer tumors P

Slide 6: Lead Oncology Product: Cynviloq
Lead Oncology Cynviloq 6Registration (Paclitaxel Trial Product polymeric Opportunity micelle)

Slide 7: Cynviloq: Next Generation Paclitaxel
Cynviloq: Maximum Generation 1st castor Biological 2nd 3rd paclitaxel ~25 polymeric diblock 7*Celgene Taxol® Cynviloq Albumin-bound nmoilcopolymer polyethylene Presentation Polyoxyethylated 130 Mean Next micelle polymer: Peak Cremophor Formulation Chemical nmGeneration size serum newMean Poly-lactid

Slide 8: Cynviloq Clinical Trials Summary
Cynviloq Total Trials >300 Possible 230 260 MBC Phase with PM-Safety: Efficacy 8Datamg/m2 Cremophor on number mg/m2 in established 1:file; 2: 2b*: 2*: 3: S. Phase (total Completed GPMBC301. and Clinical 1st Korea Chemo-naïve + Completed *safety (q3w) line of cis carbo n=80) Investigator 3patients EL

Slide 9: Comparative Response Rate
Comparative Rate Response *Overall ** 9*** Trieu Gradishar Guan (%)et al. et al. 2013. Phase et 2007. al. 2005. IG-001 3 MBC ASCO J Clin for Clinical Annual Metastatic Oncol, Results Meeting 23:7794-7803. Breast Proceedings Cancer- Interim Part I. Analysis Jun 20;25of(Suppl a Phase 18):1038. 3 Trial

Slide 10: Pilot PK Data Assessment
PilotAssessment Log-linear BE Ratio Parameters Ln(AUC0 (%) Ln(Cmax Point 110—Ln(AUC0 10 vs. PK estimate ofAlbumin-Bound Cynviloq/ Data )to Plot Albumin-bound 102.5 ) Analyses 109.1 N(n=8) and to =83.10 53 )Sample 93.98 with –Suggest Paclitaxel 126.35 –90% paclitaxel Size 126.58 power Estimate 90% CI

Slide 11: Bioequivalence Study Design (TRIBECA)
Bioequivalence -(TRIal Key (n Duration: Albumin-bound Cycle paclitaxel (90% Note: Cynviloq T 11Patients R= I27)* Parameters: B CI) Previous 1establishing 2 E paclitaxel Cynviloq historical Infusion with 3C Endpoints: weeks A™MBC trial =crossover Cynviloq (TRIal Accelerated Dose: time: +BioEquivalenc

Slide 12: TRIBECA Enrollment Status
TRIBECA 20 consistent Active Enrollment 12 Sites sitesEnrolled Sites (East with Patient 54 and Europe, pts historical Patient Patients Enrollment USA, Enrollment nab-paclitaxel Asia) On Track actively toxicity recruiting profile patients Target 54 MBC patients to establish BE exceeded in Dec 2014 Re

Slide 13: Estimated First Product Timeline
Estimated First Product BE NDA Approval FDA 2016 LAUNCH *Estimates, 2014 2015 Study 13 Filing patient filing: launch 2016 Timeline subject dosed: Q3(MBC 2015March to anddiscussions and Next 31, NSCLC): Steps* 2014with Last 2016 the patient FDA.in: January 2015

Slide 14: Resiniferatoxin (RTX) for Intractable Cancer Pain
Resiniferatoxin RTX Intractable 14 Pain Cancer (RTX): A Novel, Non-opiate Analgesic

Slide 15: Two Products for Intraganglionic or Intrathecal Use
Two the Intraganglionic: near Dorsal Cross spinal TRPV1-positive (dark Absence positive 15 treatment Injection Products brown) Sections cord* root cells dorsal of TRPV1- ganglion after for Sites root ofinjection cells Human RTX ganglion = Use intocerebrospinal or Intrathecal:fluid injection space in

Slide 16: Interim Phase 1/2 Trial Data
Summary Sponsored 6DESIGN (49-61 No toxicities injection Clinically explored improvement 16 RESULTS advanced unexpected years; injection complete OVERVIEW of meaningful Trial cancer Interim 4inAll M/ QOL(n=2) patients 2F, 6relief Data patients increased Improved MBC, optimization post- from with had

Slide 17: Next Steps for RTX Development
Next Complete trial n=45-60 OBJECTIVES 2015 for Phase End ~3 17 years (intrathecal ofSteps and 1/2 Phase patients; for 2016 trial(s) intractable for clinical 2RTX End Initiate meeting injection (intraganglionic optimization of Development development cancer Phase Phase with ) under pain 2FDA 3 meeti

Slide 18: Immunotherapy: G-MAB, Conjugation, Neukoplast
Immunotherapy G-MAB + Conjugation 18NeukoplastChemistries Proprietary Toxins Programs &

Slide 19: G-MAB: Very Diverse Proprietary Library
G-MAB: Very Proprietary RNA Freedom-To-Operate generation (over No Difficult Small High Immune Most G Size 19Protein-Coupled stacking of high Value amplification Difficult 70 Peptides Target modulation: targets Targets: Library library technology: Oncology royalties Antigen Targets: screened) divers

Slide 20: Anti-PD-L1 Exhibits Potent Immune Activity
Anti-PD-L1 T Sorrento mAb IL-2 Day Tumor *** mAbs xenograft p<0.05, 20Cell Model** Mouse (pg/mL) mAb @ Activation Growth mean Competitor 0.05 model mAb Modulation* tumor mg/mL Inhibition using (%) Exhibits volumes IFN-g H1975 (%) Potent (pg/mL) are human significantly Activity Immune NSCLC cells; re

Slide 21: Anti-PD1 Immune Activation
Anti-PD1 Immune Activation (%) C — H T PD1 Competitor Sorrento 21ell uman 2 IFN PD1Cyno Modulation* mAb IL CTLA-4 mAb gmAb (pg/mL) Human Sorrento Exhibits Control CD28 (pg/mL) Human Target mAb Excellent ICOSSpecificity Human control Activity PBS

Slide 22: Proprietary Conjugation Chemistries
Proprietary Chemistries Maleimide K-Lock Destabilizes C-Lock Enhances 22 conjugation ADC conjugation K-Lock Enable antibody stability Homogeneous andstructure C-Lock Prolongs Drug-antibody Conjugation PK ADCs profile Reduces linkage off-target not stableeffects Altered PK profile Off-target drug eff

Slide 23: Proprietary Toxins Show High Potency
Proprietary EC50 SBKR3 HCC1954 BT474 MDA-MB-361 ZR75 HCC1419 MDA-MB-453 MDA-MB-175 N87 OE-19 SKOV-3 Trastuzumab 23 Gastric (pM) Breast Gastric Breast Breast Ovarian Breast High Cancer +++ +++ was +++ +++ +++ Breast Potency 368 +++ used 215 818 Her-2 176 95139 298 124 391 +++ ++ + 150 as 72 126 164 >

Slide 24: In Vivo Proof-of-Concept of Sorrento ADCs
In Vivo VEGFR2-ADC c-MET-ADC A431 U87 24 xenograft; squamous-cell Proof-of-Concept STI-D0602 dosing STI-D0168 carcinoma twice of Sorrento weekly; cells; maytansinoid ^indicates ADCs dosing drug conjugates

Slide 25: The Immunotherapy Company Joint Venture
“The companies Independent Both Joint 25 venture Immunotherapy company willwill drawcontribute Antibody focused from NantWorks’ on to JVadvancing its Company” pipeline proteomic next of clinical generation and genomic and preclinical immunotherapies capabilities assetsand of against novel Sorrento’s

Slide 26: An Exclusive Joint Partnership
AN EXCLUSIVE CAR.TNK 26 is a trademark JOINT PARTNERSHIP owned by Sorrento Therapeutics, Inc. Neukoplast is a trademark owned by Conkwest, Inc.

Slide 27: Advancing Beyond Neukoplast
Advancing Beyond Neukoplast® (“off-the-shelf”) Proprietary Broad solid ‘GMP No over 27 clinical 40 and anti-cancer inpatients CAR-T aliquid Box’ Cellular DLTs/SAEs gene NKtumors Cell production treated library insertion cell activity Immunotherapy Therapies line (over FTO in in Proprietary Vast High

Slide 28: CAR.TNK Key Differentiators
CAR.TNK Simple: Cell Transduction characteristics Broad: MOA mechanisms Good: Safety IL-6 encephalitis; COGS manufacturing 28 Production production killing On-target limited Low: Multiple Off-the-shelf vs(“off-target CAR-T large Death through 100%: CAR-T: due of for CAR-modified Cardiotoxicity; MOAs

Slide 29: Unmodified Neukoplast Phase 1 Studies
Unmodified Phase More Advanced Many Promising No 29 DLTs; than 1 Studies patients only metastatic activity 40Neukoplast patients received 1 “grade against disease treated multiple 4Clinically SAE” different refractory dosing (hypoglycemia Validated cancer to regimens chemo, types, In Several likely

Slide 30: Neukoplast Mixed Lymphocyte Reaction Assay
Neukoplast T Mixed Gold: 35000 CPM 20000 25000 130000 0-D 5000 Lymphocytes Co-cultured 30 5000 0000 cell 15000 Donor Proliferation PHA Aqua: Lymphocyte Allogeneic do with 1Donor from notNeukoplast stimulate 2measured Reaction 2healthy Donorallogeneic donors (7 (MLR) using Neukoplast days)co-cultured

Slide 31: CAR.TNK: Clonal and Titratable
CAR.TNK: Clonal Multiple Engages Titratable: 31 cell the killing repeat lines CAR-modified adaptive mechanisms—CAR-targeted expressing dosing immune option; Neukoplast onesystem or controllable more through CARs dose as cytokine towell establish exposure as secretion broad atorange intrinsic manage

Slide 32: Serial Killing and Homing of Her2.TNK
Serial IN Homing Inhibition Growth “Serial Selective Schoenfeld 32 VIVOKilling killing” inhibition tocytotoxicity PRECLINICAL ofHer2 etHer2+ of al.ofHer2+ expressing Mol Her2+ and RCC Therapy, (spares killing Cells target metastasis MOUSE tumors by correlate normal in cells Her2.TNK press DATA even

Slide 33: Her2.TNK Mechanism of Action
Her2.TNK Her2+ Schoenfeld 33 Cancer In et Action: al. Cells Mol Targeted Therapy, and in press Serial Killing of

Slide 34: Her2.TNK Anti-Glioma Activity in Mice
Her2.TNK Tumor Intracranial xenografts Schoenfeld 34 homing in Demonstrate et LN-319 NSG al.ofMol CAR.TNKs mice glioblastoma Therapy, TumorinHoming press and Potent Anti-Glioma Activity in Mice

Slide 35: Prospective CAR.TNK Target List
Prospective (Initial Target EGFRviii.TNK EphA3.TNK L1CAM.TNK CSPG4.TNK BCMA.TNK ROR1.TNK PSMA PSCA.TNK PDL1.TNK CS1.TNK CD123.TNK CD19.TNK CD22.TNK CAR Lead Profit EGFRviii.TNK, Therapeutics, 35 company targets sharing Potential or List) Myeloma CAR.TNKs Myeloma, CLL, Prostate CLL, jointly Glioma, A

Slide 36: Next Steps 2015-2016
Next2015 H1 H2 2016 36 Steps IND-enabling Generation for CAR.TNK studies, of CARs and evaluation Development IND submission, of stable CAR.TNK and initiation celloflines Phase 1 studies

Slide 37: A Comprehensive Cancer Company
A Comprehensive Deep Novel Small Molecules Cytotoxics CYNVILOQ™ Cancer Targeted MYC TRAIL Bispecific (Partnership CYNVILOQ, 37 and inhibitor Biologics breakthrough Pain modulator Therapy Complementary Abs ADC Therapy Immunotherapy with CAR.TNK, Intractable Anti-VEGR2 PD1, Tumor-attacking Cell Conkwe

Slide 38: Contact
Cancer607-4057 Next-Generation George CONTACT: Executive guy@sorrentotherapeutics.com (661) Therapeutics UyVice Henry President (858) Ji, Ph.D. 668-6923 and CCO hji@sorrentotherapeutics.com President and CEO
Source: SEC EDGAR · 8-K filed Jan 12, 2015
More decks from Sorrento Therapeutics, Inc.
Presentation (August 2023)9 slides · Aug 1, 2023
SPAC Merger (March 2022)21 slides · Mar 18, 2022
Technical Presentation (January 2022)13 slides · Jan 21, 2022
SPAC Merger (December 2021)57 slides · Dec 13, 2021
Technical Presentation (November 2021)9 slides · Nov 29, 2021
Investor Presentation (September 2021)37 slides · Sep 13, 2021